Flagship Pioneering announced on Monday 16 November that it had committed an initial £100 million to set up the Flagship Origination Lab in London, its first dedicated company-building unit outside the US. Flagship announcement
The unit will test ideas for new businesses using AI in human health, environmental science and other fields. Flagship plans to recruit and train about 50 people in the UK. Fierce Biotech report
Flagship told European Biotechnology that the £100 million would cover setting up the lab, hiring, developing its research capabilities and investing in its first ventures. Chief executive Noubar Afeyan said the firm hoped to attract another £500 million through partnerships. European Biotechnology report
Flagship’s earlier UK work
Flagship opened its London office in 2023. In November that year it signed a memorandum of understanding with the UK government covering possible collaboration on clinical trials, work with UK genomics organisations and a search for potential British manufacturing sites for its companies. UK government announcement
Flagship’s first company based in both countries was Quotient Therapeutics, unveiled in November 2023 with research sites in Cambridge in the UK and Cambridge, Massachusetts. Quotient studies how genetic differences between cells in the same person could help researchers identify possible drug targets. Quotient launch announcement
Monday’s announcement came during London Life Sciences Week. Its programme listed Flagship senior partner Junaid Bajwa as moderator of a session on AI in drug discovery, alongside a separate discussion on genomics and health data. London Life Sciences Week programme
AI-generated illustration of laboratory equipment and a network diagram.
Comments are disabled.












